CHEMELECTIVA’s Team wishes you all the best for a happy Holiday Season and a Happy New Year! 2024 promises to be a year full of commitments and news for Chemelectiva. As previously announced, with the new year, the works started in March 2023 for the construction of the new cGMP manufacturing plant will be completed....

In the current month, our CEO Graziano Castaldi attended ChemOutsourcing, the largest trade show dedicated to APIs and Pharmaceutical Ingredients based in the United States. The sixteenth edition, which took place September 6-8, 2023 at the Parsippany Hilton in Parsippany, NJ, was again attended this year by many representatives of the chemical and pharmaceutical industry,...

Clascoterone is an androgen receptor inhibitor developed as a cream and solution for the treatment of androgen-dependent skin disorders, including androgenetic alopecia and acne vulgaris. In August 2020, 1% clascoterone cream received its first approval in the United States for the topical treatment of acne vulgaris in patients 12 years of age and older. Clinical...

Ruxolitinib, a Janus kinase inhibitor with selectivity for the JAK1 and JAK2 subtypes of this enzyme, was approved in 2011 by the FDA for the treatment of patients with myelofibrosis and polycythemia vera, has now also received marketing authorization from the European Commission for the treatment of nonsegmental vitiligo. Chemelectiva has developed a new efficient...